Health issues
Thrombotic Thrombocytopenic Purpura (TTP)
What is Thrombotic Thrombocytopenic Purpura? TTP or Thrombotic Thrombocytopenic Purpura is a rare disease of the group known as thrombotic  microangiopathies. These are diseases  in which the platelets or thrombocytes (involved in coagulation) clog together in an abnormal manner leading to the formation of blood clots.  This phenomenon causes three problems:A reduction in the number of available platelets = Thrombocytopenia.The red blood cells collide with these clots and break up leading to a reduction in number = Anaemia.The clots can block the blood vessels and reduce the oxygenation of tissues with possible serious consequences for the heart, brain, kidneys, etc.  A number of causes can be responsible for the occurrence of these thrombotic microangiopathies. The TTP is caused by the deficiency of a protein known as   "Adamts 13". This deficiency is most frequently due to the presence of an antibody (= immune TTP) or otherwise it may be a genetic anomaly (congenital TTP).   Treatment TTP must be treated as a vital emergency. Without treatment the mortality rate is 90%. A rapid diagnosis is essential followed by optimal treatment at an expert centre.  Initial treatment of immune TTP consists of two action plans:1.Acute treatmentIncreasing the level of Adamts 13 proteins by means of plasma exchanges: The plasma (the liquid component of the blood that contains cells) is replaced with healthy plasma that serves to increase Adamts 13 levels and remove antibodies.    Since 2019 an innovative medicine specific to TTP has made it possible to prevent the platelets from attaching themselves to each other, thereby resolving the three problems indicated above. This has permitted a clear improvement in the treatment of acute stage patients. Our centre always has this medicine on hand for rapid administration.    2.Fundamental treatmentStopping the production of antibodies that act against Adamts 13. First line treatment consists of the administration of corticoids and a monoclonal antibody that targets the cells that produce the antibodies  Treatment of congenital TTP is based on the administration of plasma. The administration of  synthetic Adamts 13 is not yet reimbursed but is accessible.  All persons suffering from TTP require lifelong monitoring by a haematologist specialising in this type of pathology.    Our specialists Advice TTP can present various and variable symptoms as it can affect a number of organs. The primary clinical manifestation is abnormal bleeding, major hematomas or petechiae (multiple small red/violet marks on the skin).  More severe symptoms can be the signs of a heart attack or stroke.  A blood test showing anaemia and a thrombocytopenia can quickly suggest the diagnosis .Useful links:   Thrombotic Microangiopathies - MaRIH – Rare Immuno-Haematological Diseases Health Network National Reference Centre Microangiopathies TTP Community - Home (Dutch language site)  Make an appointment Focus Our hematology team has gained extensive experience in managing this condition and regularly receives requests for the care of patients from external centers.We regularly collaborate with expert centers from various European countries (France, United Kingdom, Italy).We participate in multidisciplinary consultation meetings with French expert centers. Discover our Hematology Department
Thrombotic Thrombocytopenic Purpura (TTP)
Health issues
Ideopathic intercranial hypertension
What is idiopathic intercranial hypertension? Idiopathic intercranial hypertension (IIH), also known as a pseudotumor cerebri, is a condition characterised by high pressure in the cerebrospinal fluid (CSF) without any identifiable cause revealed by imaging examinations. It is more common in women of childbearing age or who are overweight. SymptomsThe symptoms of IIH include:Severe and persistent headaches, often worse when lying down.Blurred or double vision.Temporary loss of vision.Ringing in the ears (pulsatile tinnitus).Nausea and vomiting.Swelling of the optic nerve   (papillary oedema) visible during an ophthalmological examination. Treatment Imaging examinationsTo identify IIH and exclude other causes a number of imaging examinations are carried out:  Brain MRI: to visualise the brain structures and  exclude anomalies such as tumours or malformationsMagnetic Resonance Angiography (MRA): to evaluate the cerebral veins and rule out a cerebrovascular thrombosis.  A CT scan of the brain: sometimes used in an emergency to rule out other causes of high intracranial pressure.Medical pathwayPatients with IIL need to consult  number of specialists for comprehensive treatment as a matter of urgency to avoid any deterioration of  the visual function: GP: for an initial assessment of symptoms and to direct the patient to the appropriate specialists.  Neurologist: principal specialist in diagnosing and managing IIH.  Ophthalmologist: to evaluate the effects of the IIH on vision and to monitor the papillary oedema.  Neuroradiologist: to interpret the brain imaging examinations.Neurosurgeon or interventional neuroradiologist: if surgery or endovascular intervention is necessary.TreatmentIIH treatment seeks to reduce the intracranial pressure and prevent any loss of vision:  Weight loss: recommended for overweight patients, this is often effective in alleviating symptoms.Medicines:  Acetazolamide: A diuretic that reduces the production of CSF and is a first line treatment with a high level of evidence.  Repeated lumbar punctures: to drain off excess CSF and used in the case of severe symptoms.  Surgery:  Optic nerve decompression: to prevent irreversible loss of vision in the case of severe papillary oedema.  Cerebrospinal shunt: to drain off the CSF if other treatments fail.  Interventional neuroradiology: venous sinus stenting to improve drainage of venous blood and reduce intracranial pressure when these veins narrow.  Multidisciplinary discussion  IIH management requires a multidisciplinary approach that includes meetings between neurologists, ophthalmologists, interventional neuroradiologists, neurosurgeons and other health professionals to discuss complex cases and coordinate treatment  Follow upThe monitoring of IIH patients is crucial and includes:  Regular vision monitoring: by an ophthalmologist to detect any deterioration.  Neurological monitoring: to assess the effectiveness of treatment and make adjustments when necessary.  Regular weight evaluations: plus dietary advice for overweight patients.Regular imaging examinations: to monitor intracranial pressure and the condition of brain structures.The follow up is carried out by a multidisciplinary team to optimise the clinical results and improve the quality of life of patients.  Discover our Interventional NeuroRadiology Department Our specialists Prendre rendez-vous
Ideopathic intercranial hypertension
Article
Bronchiolitis: how can you protect your baby against RSV this winter?
As winter approaches, the Queen Fabiola Children’s University Hospital (HUDERF) and Erasme Hospital are launching a new RSV immunisation campaign. A single injection can protect your baby throughout the period when the virus is circulating most widely. Why protect babies against RSV before winter?Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis in babies. The virus circulates mainly during the autumn and winter months and is highly contagious. It spreads through coughs and sneezes, as well as via hands and contaminated objects.Most children recover without serious complications. In young babies, however, RSV can cause breathing or feeding difficulties and may sometimes require hospital admission.The aim of the campaign is therefore simple: to protect babies before they are exposed to the virus during the winter months.RDV HUDERF      RDV HÔPITAL ERASMEIs my baby eligible for the 2026 campaign?This mainly depends on your baby's date of birth and, in some cases, on whether they have particular risk factors.Was your baby born between 16 March and 30 September 2026?Your baby is eligible for the immunisation campaign running from 1 September to 31 October 2026 at the Children's Hospital and Erasme Hospital.Was your child born before 16 March 2026?Some children with specific risk factors may also be eligible, depending on factors such as their age, prematurity or certain chronic conditions. Speak to your paediatrician, who can check whether your child is eligible for immunisation.Will your baby be born during the RSV season?There is no need to wait for a catch-up campaign. When immunisation is recommended, it can be given from birth, ideally in the maternity unit.How can a single injection protect my baby?Nirsevimab is not a vaccine. It is a monoclonal antibody. Instead of prompting your baby's immune system to produce its own antibodies, it provides antibodies directly to help neutralise RSV.This means that protection begins quickly after the injection.A single intramuscular injection provides protection for at least five months, helping to cover the period when RSV is most widely circulating.Immunisation significantly reduces the risk of severe RSV infection and RSV-related hospital admission.Vaccination during pregnancy or immunisation of the baby: what is the difference?There are two ways to protect a newborn baby against RSV.The first option is vaccination of the mother during pregnancy. The mother's immune system produces antibodies against RSV, which are then passed to the baby through the placenta. This means the baby is already protected from birth.The second option is to immunise the baby directly with a monoclonal antibody.Both approaches therefore have the same goal, but work in different ways: in one case, the baby receives antibodies from the mother; in the other, the antibodies are given directly to the baby.In most cases, one of these two approaches is sufficient.When and where can my baby be immunised?The catch-up campaign runs from 1 September to 31 October 2026, with dedicated paediatric appointments available at the Children's Hospital and Erasme Hospital.The appointment is quick and ensures your baby receives the injection before RSV circulation reaches its seasonal peak.How can I make an appointment?Children's Hospital: 02 477 31 20Erasme Hospital: 02 555 55 55
Rich page
NATUS – Medical and psychosocial support during the perinatal period
Medical and psychosocial support around childbirth. NATUS is a multidisciplinary team at Erasme Hospital providing preventive, medical and psychosocial support around childbirth.The team supports expectant parents and families experiencing vulnerability or who feel they need additional support before, during or after pregnancy.Who is NATUS for?NATUS primarily supports expectant mothers and mothers receiving care at Erasme Hospital.Support can begin from the time parents start planning for a child, including as part of an assisted reproduction pathway, and can continue throughout pregnancy and after the birth of the baby.Support may be provided at the request of the patient or her family, or following a referral from a healthcare professional when vulnerability is identified during pregnancy or around the time of birth.What support does NATUS provide?Every situation is different. The NATUS team therefore provides support tailored to the needs of the mother, baby and family.This may include:an assessment of the medical, psychological and social situation;support during pregnancy and after the birth;short-term follow-up tailored to the perinatal period;particular attention to the bond between parent and baby;referral to specialised professionals or services when additional or longer-term support is required.Admission to a psychiatric unit may also be considered when necessary.‘Nurture and Play’ groups, designed to support the parent–baby bond, are also currently being developed.A multidisciplinary teamNATUS brings together professionals from a range of disciplines who work closely to provide coordinated support:Child and adult psychiatristsChloé Leemans, Laurence WeetsObstetricians and gynaecologistsClotilde Lamy, Siham ZaytouniPaediatricianAdrien GuillaumePsychologistsJulie Venegoni, Maelle Hector, Aline CuvellierSocial workersLaurence Bonkain, Barbara GiannetoMidwivesCharlotte Delvigne, Marta VaqueroNATUS coordinatorPauline EondesThe team meets weekly and remains in regular contact to ensure continuity and coordination of care.Working as part of a care networkNATUS works closely with the different H.U.B. teams involved in pregnancy, childbirth and early childhood.After the birth, the team works in particular with the Parent–Baby Unit at the Laeken site, the APPI units and day units for young children, as well as with professionals at the Children's Hospital (HUDERF) specialising in early childhood care and support.When necessary, families may also be referred to SOS Enfants or to youth support and protection services (SAJ/SPJ).ContactNATUS – Erasme HospitalTel.: 02 555 49 44Email: natus [dot] perinat [dot] erasme [at] hubruxelles [dot] be (natus[dot]perinat[dot]erasme[at]hubruxelles[dot]be)
Rich page
Pediatric spinal dysraphism and spinal deformities – Symposium
Image A full-day multidisciplinary update on pediatric spinal dysraphism and spinal deformities Date & Location:November 6, 2026 – Musée de la MédecineRegistrationPROGRAM  Location: Musée de la MédecineCampus Erasme – Place FacultaireRoute de Lennik, 8081070 BruxellesBelgiqueInfo:Symposium [dot] Paeds [dot] Neurosurgery [at] hubruxelles [dot] be (Symposium[dot]Paeds[dot]Neurosurgery[at]hubruxelles[dot]be) 
Information
Uncancelled appointments
Appointments that are neither attended nor cancelled are a major cause of delays in our hospitals. If you are unable to keep your appointment, please let us know as soon as possible. Any appointment that is missed and not cancelled at least 48 hours before the scheduled time will incur a fee: €30 for a consultation€100 for an MRI scan, X-ray or CT scan€200 for a procedure There are several ways to cancel an appointment: Through the MyHUB app, if you originally booked your appointment via the appUsing the cancellation forms available on our websiteOr by calling 02 555 55 55 and following the menu options until you reach the relevant department.  You can cancel your appointment up tu 48 hours before with no fees incurred
Health issues
Congenital hypothyroidism
Department overview The Adult Endocrinology Clinic provides diagnosis and follow-up for adult patients with an endocrine problem, that is, a condition affecting the secretion of a hormone (excessive or insufficient secretion) and/or the gland that secretes it. The department therefore manages conditions affecting the thyroid, parathyroid glands, adrenal glands, gonads (ovaries and testicles), and pituitary gland. Since 2016, the Endocrinology Department of Erasme Hospital, in association with the Queen Fabiola Children’s University Hospital (HUDERF) for paediatric care, has been part of ENDO-ERN (European Reference Network for Rare Endocrine Conditions), the European Reference Network for rare endocrine diseases.This network aims to improve access to high-quality care for patients with rare endocrine disorders. It supports clinical research and contributes to the creation of registries listing patients receiving follow-up for rare conditions, in order to promote knowledge sharing and improve clinical practice. The management of rare endocrine diseases is multidisciplinary. Regular consultations are organised to discuss complex cases, with numerous specialists within our institution, as well as during virtual consultations with recognised European experts through the ENDO-ERN network or during international multidisciplinary case meetings (France).Some endocrine diseases begin at birth or during childhood and require lifelong treatment and follow-up. Transition consultations have been provided for many years with our paediatric colleagues at HUDERF to ensure the smoothest possible transition from paediatric to adult care. What are rare congenital thyroid diseases? Rare congenital thyroid diseases are conditions that are most often present from birth and affect the functioning of the thyroid gland. In most cases, they are congenital hypothyroidism, meaning insufficient production of thyroid hormones. Thyroid hormones are essential for growth, but also and above all for the normal development of the brain during fetal life and childhood. In adulthood, they are primarily involved in regulating body temperature (thermoregulation), controlling metabolism (energy expenditure), fertility, intestinal transit, heart rate and mood. Hypothyroidism occurring in adulthood is most often acquired and has various causes (autoimmunity, thyroid surgery, medication, etc.). It does not fall into the category of rare endocrine diseases, unlike congenital hypothyroidism.The latter may be caused by an absent thyroid (agenesis), an abnormally formed thyroid (dysgenesis), or a defect in the synthesis of thyroid hormones resulting from a mutation in one of the key enzymes (proteins) involved in hormone production. They are most often detected very early, during the first days of life, through neonatal screening. This enables rapid and effective management, preventing the harmful effects of thyroid hormone deficiency on the child’s brain and musculoskeletal development. During pregnancy, the mother provides the fetus with thyroid hormones, thereby compensating for the defect in the fetal thyroid’s hormone synthesis. However, once born, the affected baby no longer benefits from its mother’s thyroid hormones and must therefore promptly receive oral hormone replacement therapy.Another category of rare congenital thyroid diseases consists of disorders of the metabolism, transport and action of thyroid hormones, including syndromes of resistance to thyroid hormones. These conditions are very rare (1/19,000–1/40,000 births) and are caused by genetic abnormalities affecting one of the thyroid hormone receptors (there are two types). Thyroid hormones are produced in sufficient quantities, but are unable to act optimally in tissues containing the mutated receptor (brain, liver, heart, muscle and bone). The severity and type of symptoms vary considerably depending on the mutation. For the most common forms of these rare disorders, which are also the least severe, diagnosis is most often made following so-called “discordant” thyroid function tests (with an unusual profile) performed during routine blood tests or as part of family screening after a known familial mutation has been identified.  Diagnosis and management Congenital hypothyroidism is screened for in newborns. A drop of blood is taken from the newborn’s heel between the 2nd and 5th day of life and placed on filter paper before being analysed. Parents are recalled for an endocrinology consultation if the screening test result is abnormal. Additional tests are performed to confirm the diagnosis (a follow-up blood test) and determine its cause (thyroid ultrasound and scintigraphy). Treatment consists of early replacement therapy with thyroid hormones, started in the first days of life. This treatment is simple, well tolerated and enables the child to develop normally. As with acquired hypothyroidism, the aims of continued follow-up into adulthood are to ensure proper metabolic function, fertility and an optimal quality of life in all areas (physical, psychosocial and professional).Regular clinical and biological follow-up is essential in order to adjust the doses as the child grows, as well as in response to changing needs in certain situations (weight fluctuations, interactions with other medicines, digestive absorption problems, fertility, pregnancy, etc.).Medical follow-up must continue throughout life. Providing patients and families with information and support is essential to ensure treatment adherence and long-term quality of life.In the most common cases of resistance to thyroid hormones, symptoms are mild and patients generally do not require specific treatment. However, this is a difficult diagnosis to make and requires the exclusion of other conditions through specific tests (including genetic analysis for confirmation), with a risk of diagnostic error that may lead to unnecessary thyroid surgery or drug treatment. Follow-up is also essential, as symptoms may evolve and require drug treatment. Care pathways File hypothyroidie_congenitale_.pdf File maladies_du_metabolisme_transport_et_action_des_hormones_thyroidiennes.pdf Transition to adulthood During adolescence, a gradual preparation for the transition to adult care is organised. This stage helps strengthen the young patient’s autonomy, ensure continuity of medical follow-up, and transfer all the necessary information to the specialised adult service. The transition is planned in collaboration with the patient, their family, and the paediatric and adult care teams. Focus / Search Patients are treated by a qualified adult endocrinologist. Hormone assays and genetic tests are carried out in a specialised laboratory. Genetic counselling is offered. An on-call service is available 24 hours a day. Our centre is actively involved in improving knowledge and care for patients with rare endocrine diseases.A local registry of cases of congenital hypothyroidism and thyroid hormone resistance has been established, and the number of new cases managed is continuously reported to the European ENDO-ERN registry. The aim is to optimise follow-up practices and compare care between different specialised centres. The team receives ongoing training, participates in congresses and seminars, initiates and collaborates on single-centre and multicentre studies, and publishes in the field of thyroid disorders. It also provides training and teaching for students and doctors in training. Our specialists
Congenital hypothyroidism
Health issues
Hyperparathyroidism
Department overview The Adult Endocrinology Clinic provides diagnosis and follow-up for adult patients with an endocrine problem, i.e. a condition affecting the secretion of a hormone (excessive or insufficient secretion) and/or the gland that secretes it. The department therefore manages conditions affecting the thyroid, parathyroid glands, adrenal glands, gonads (ovaries and testicles) and pituitary gland.Since 2016, the Erasme Hospital Endocrinology Department, together with the Queen Fabiola Children’s University Hospital (HUDERF) for paediatric care, has been part of ENDO-ERN (European Reference Network for Rare Endocrine Conditions), the European Reference Network for rare endocrine diseases.The mission of this network is to improve access to high-quality care for patients with rare endocrine disorders. It supports clinical research and contributes to the creation of registries listing patients monitored for rare conditions, in order to promote knowledge-sharing and improve clinical practices. The management of rare endocrine diseases is multidisciplinary. Regular case discussions are organised for complex cases with numerous specialists within our institution, as well as through virtual consultations with recognised European experts via the ENDO-ERN network or during international multidisciplinary case conferences (France).Some endocrine diseases begin at birth or during childhood and require lifelong treatment and follow-up. Transition consultations have been provided for many years with our paediatric colleagues at HUDERF to ensure the smoothest possible transition from paediatric to adult care. What is primary hyperparathyroidism? Primary hyperparathyroidism results from overactivity (hyperfunction) of the parathyroid glands, located behind the thyroid gland in the neck. These glands secrete parathyroid hormone (PTH), a hormone that is essential for regulating calcium levels in the blood. Primary hyperparathyroidism is the third most common endocrine disorder.In the vast majority of cases, this overactivity is caused by a parathyroid adenoma, that is, a small benign tumour that develops in one of the four parathyroid glands. More rarely, several glands are affected (referred to as hyperplasia or multiglandular disease), particularly in certain genetic disorders (for example, multiple endocrine neoplasia type 1 [MEN1]) or in patients with severe chronic kidney disease.Excess parathyroid hormone causes an increase in the level of calcium in the blood (hypercalcaemia). This increase may cause various symptoms, such as excessive thirst, nausea, vomiting, constipation or kidney stones.In the longer term, excess parathyroid hormone may affect the bones (osteopenia, osteoporosis and an increased risk of fractures) and the kidneys (nephrocalcinosis and kidney failure).Today, primary hyperparathyroidism is increasingly detected at an early stage, during a simple blood test performed for another reason. Even in the absence of symptoms, a complete assessment is necessary to evaluate the effects of the disease on the bones and kidneys. Appropriate management can prevent complications and sustainably improve patients’ quality of life. Care management Surgery of the parathyroid gland or glands responsible for the hypersecretion is the standard treatment for primary hyperparathyroidism and leads to a cure in the majority of cases.The indication for surgery and the optimal timing of the procedure are determined after a comprehensive assessment of any potential complications, taking the patient’s age and various clinical and biological criteria into account.Management must be multidisciplinary and involves endocrinologists, surgeons specialising in parathyroid surgery, radiologists and nuclear medicine physicians, in order to precisely locate the abnormal glands before surgery. Depending on the situation, geneticists, nephrologists and rheumatologists may also be involved in the patient’s care.At our centre, a multidisciplinary meeting dedicated to parathyroid disorders is held every month to discuss complex cases and define the most appropriate treatment strategy.The aim is to support each patient in understanding their condition, provide personalised care and sustainably improve their quality of life.Multidisciplinary teamAdult endocrinology: see the doctors responsible for the conditionNuclear medicine: Dr Magdalena MilevaParathyroid surgery: Dr Maria RuizNephrology: Dr Caroline La, Dr Delphine KemlinRadiology: Dr Isabelle Delpierre, Dr Yolène LefebvreRheumatology: Prof. Muhammad Soyfoo, Dr Joëlle MargauxGenetics: Dr Isabelle Vandernoot Patient advice A balanced diet, adequate hydration (at least 2 litres of water per day), moderate salt consumption, correction of any vitamin D deficiency, and regular physical activity all contribute to maintaining good mineral balance. In the event of unusual acute symptoms (feeling unwell, palpitations, severe pain, haematuria), it is recommended that you promptly consult an Emergency Department. If you have any doubts or questions, the medical team remains your preferred point of contact to adapt your care. Focus / Search Patients are cared for by a specialist endocrinologist. Hormone assays and genetic analyses are performed in a reference laboratory. Specialist on-call cover is provided 24 hours a day.Our centre is actively involved in improving the diagnosis and management of primary hyperparathyroidism, notably through the creation of a dedicated diagnostic unit for thyroid nodules and parathyroid disorders.This “fast-track” outpatient unit, located within the Nuclear Medicine Department of the Jules Bordet Institute, makes it possible to perform the main examinations required for the assessment on the same day: cervical ultrasound targeting the parathyroid glands, renal ultrasound, fluorocholine PET (a tracer offering excellent sensitivity for detecting parathyroid adenomas) and bone densitometry. The results are then discussed during the consultation with the endocrinologist in order to establish an accurate diagnosis and propose the most appropriate treatment strategy. Our specialists Associated services
Hyperparathyroidism
Health issues
Hypoparathyroidism
Department overview The Adult Endocrinology Clinic provides diagnosis and follow-up for adult patients with an endocrine problem, that is, a condition affecting the secretion of a hormone (excessive or insufficient secretion) and/or the gland that secretes it. The department therefore manages conditions affecting the thyroid, parathyroid glands, adrenal glands, gonads (ovaries and testicles) and pituitary gland.Since 2016, the Endocrinology Department of Erasme Hospital, together with the Queen Fabiola Children’s University Hospital (HUDERF) for the paediatric component, has been part of ENDO-ERN (European Reference Network for Rare Endocrine Conditions), the European Reference Network for rare endocrine diseases.The mission of this network is to improve access to high-quality care for patients with rare endocrine disorders. It supports clinical research and contributes to the creation of registries listing patients monitored for rare conditions, in order to promote knowledge sharing and improve clinical practices. The management of rare endocrine diseases is multidisciplinary. Regular consultations are organised to discuss complex cases, involving numerous specialists within our institution, as well as through virtual consultations with recognised European experts via the ENDO-ERN network or during international multidisciplinary case-review meetings (France).Some endocrine diseases begin at birth or during childhood and require lifelong treatment and follow-up. Transition consultations have been provided for many years in collaboration with our paediatric colleagues at HUDERF, to ensure the smoothest possible transition from paediatric to adult care. What is hypoparathyroidism? Hypoparathyroidism and pseudohypoparathyroidism (recently referred to as IPPSD type 2, or “Inactivating PTH/PTHrP Signaling Disorder”) are rare diseases of the parathyroid glands. The parathyroid glands are four small glands located next to the thyroid gland that secrete parathyroid hormone (PTH), a hormone essential for regulating calcium and phosphorus levels in the body. These diseases cause a decrease in the level of calcium in the blood. This hypocalcaemia can cause a range of symptoms, depending on its severity and how quickly it develops: cramps, muscle stiffness, tingling in the extremities, unusual fatigue, irritability, attention and concentration problems, and seizures.The disease may be present from birth or childhood, as part of a genetic syndrome, or may be acquired later in life, most often as a complication of thyroid surgery (thyroidectomy). Pseudohypoparathyroidism is a particular and very rare form of hypoparathyroidism, linked to a genetic mutation that makes the body resistant to the action of parathyroid hormone. There is no defect in PTH secretion, but the mutation impairs its action. The disease generally appears during childhood and is associated with resistance to other hormones, most often thyroid hormones, but sometimes also growth hormone or the hormones involved in puberty. Care/management In most cases, the diagnosis is suspected on the basis of symptoms suggestive of hypocalcaemia (cramps, tingling, etc.) and confirmed by a blood test (calcium, phosphate, PTH levels, etc.). In the majority of cases, hypoparathyroidism in adults occurs after a thyroidectomy. In other cases, genetic testing may be necessary to rule out hereditary conditions and to guide the diagnosis and management. The aim of treatment is to maintain calcium and phosphate levels as close to normal and as stable as possible, in order to alleviate symptoms and prevent complications. Treatment generally combines calcium and active vitamin D supplementation, with individualised adjustment. New molecules that are very similar in structure to parathyroid hormone (= “PTH analogues”) are currently being evaluated in clinical studies and are already being used in some European countries for adult patients.Management is multidisciplinary, involving endocrinologists, dietitians (advice on dietary calcium intake) and, depending on the situation, geneticists, nephrologists and psychologists. The aim is to provide patients with the best possible support in understanding their condition and treatment, and to sustainably improve their quality of life. Patient advice Adherence to treatment and regular medical follow-up are essential. It is important to respect the number of doses and the prescribed doses of the supplements, and to report any change in general condition to the healthcare team, such as unusual fatigue or persistent or recurrent symptoms of hypocalcaemia. A balanced diet also contributes to maintaining good mineral balance. In the event of unusual acute symptoms (discomfort, severe spasms, altered consciousness), it is recommended to go to the Emergency Department without delay. If in doubt, the medical team remains the best point of contact for adapting the care plan. Care pathway File trajet-de-soins.pdf Transition to adulthood During adolescence, a gradual preparation for the transition to adult care is organised. This stage helps strengthen the young patient’s autonomy, ensure continuity of medical follow-up and transfer all the necessary information to the specialised adult service. The transition is planned in collaboration with the patient, their family, and the paediatric and adult teams. Focus / Research Patients are treated by a licensed adult endocrinologist. Hormone assays and genetic tests are performed in a specialised laboratory. An on-call service is available 24 hours a day. Our centre is actively involved in improving knowledge and care for patients with rare endocrine diseases. A local registry has been established. A dedicated European ERN database for hypoparathyroidism will be set up shortly. The aim is to better understand the course of the disease, optimise follow-up practices, and compare management approaches between different specialised centres. The team undertakes continuous professional development, participates in congresses and seminars, initiates and collaborates on studies, and publishes in the field of parathyroid disorders. It also provides training and teaching for students and doctors in training. Our specialists
Hypoparathyroidism
Health issues
Uveitis
Our specialists Associated department
Uveitis
Health issues
Turner syndrome
Presentation of the department The Adult Endocrinology Clinic provides diagnosis and follow-up for adult patients with an endocrine disorder, that is, a condition affecting the secretion of a hormone (excessive or insufficient secretion) and/or the gland that secretes it. The department therefore manages conditions affecting the thyroid, parathyroid glands, adrenal glands, gonads (ovaries and testes) and pituitary gland.Since 2016, the Endocrinology Department of Erasme Hospital, in partnership with the Queen Fabiola Children’s University Hospital (HUDERF) for paediatric care, has been part of ENDO-ERN (European Reference Network for Rare Endocrine Conditions), the European Reference Network for rare endocrine diseases.The mission of this network is to improve access to high-quality care for patients with rare endocrine disorders. It supports clinical research and contributes to the creation of registries listing patients receiving follow-up for rare conditions, in order to promote the sharing of knowledge and the improvement of clinical practices. The management of rare endocrine diseases is multidisciplinary. Regular consultations are organised to discuss complex cases with numerous specialists within our institution, as well as through virtual consultations with recognised European experts via the ENDO-ERN network or during international multidisciplinary consultation meetings (France).Some endocrine diseases begin at birth or during childhood and require lifelong treatment and follow-up. Transition consultations have been provided for many years in collaboration with our paediatric colleagues at HUDERF, to ensure the smoothest possible transition from paediatric to adult care. What is Turner syndrome? Turner syndrome is a genetic condition associated with an abnormality of the sex chromosomes. It affects approximately 25 to 50 girls per 100,000. It is characterised by the presence of one normal X chromosome and the complete or partial absence of the second X chromosome. When all cells present this abnormality, it is referred to as X monosomy (45,X). In some people, only a proportion of cells is affected; this is known as mosaicism. The manifestations of the condition may be more or less pronounced depending on the type of chromosomal abnormality, although the karyotype does not always make it possible to predict the severity of the condition or the risk of long-term complications.The two main characteristics of Turner syndrome are:A short stature Premature ovarian insufficiency, resulting in delayed or absent puberty, amenorrhoea (absence of menstrual periods) and, most often, infertility.Turner syndrome may also be associated with other conditions requiring regular medical follow-up, including:Cardiovascular abnormalities (heart valve abnormalities, aortic involvement, high blood pressure);Abnormalities in the shape of the kidneysOverweight, obesity and/or diabetesAutoimmune diseases such as autoimmune thyroiditis Recurrent ear infections with residual hearing lossSome patients also have difficulties with certain types of learning and visuospatial difficulties.The manifestations of the syndrome vary considerably from one person to another. Some patients have few clinical signs and therefore require less intensive medical follow-up, whereas others require multidisciplinary follow-up throughout their lives. Diagnosis The diagnosis may be made at different stages of life, depending on the clinical manifestations. It may be suspected before birth, during an ultrasound scan showing certain suggestive abnormalities, or through non-invasive prenatal testing (NIPT). The diagnosis is then confirmed by chromosomal analysis performed on a chorionic villus sample or by amniocentesis.After birth, the diagnosis is most often suspected in the presence of:A reduced growth rate or short stature during childhood;An absence of or delayed puberty during adolescence; Amenorrhoea or infertility during adolescence or adulthood.Certain physical characteristics may suggest the diagnosis, such as the position of the ears, hairline, the presence of a shorter finger, and the shape of the eyes and neck. However, these signs are inconsistent and are often less suggestive than abnormalities of growth and pubertal development.Recurrent ear infections, hearing loss, learning difficulties or the discovery of a heart abnormality may also lead to suspicion of the diagnosis.The diagnosis is confirmed by a karyotype performed on a blood sample, which reveals the complete or partial absence of an X chromosome. A hormonal assessment is also performed to evaluate ovarian function, particularly by measuring oestradiol and other hormones related to ovarian function. Care management Care is multidisciplinary and individualised. It includes, in particular, growth hormone treatment to improve final height, hormone replacement therapy to induce and then maintain puberty, as well as regular monitoring of cardiovascular, endocrine, metabolic, hearing and bone-related complications. If they wish to have children, patients are referred to the fertility clinic to discuss the various options available to them and receive appropriate support.Psychological, neuropsychological and/or speech therapy support may also be offered according to each patient’s needs.Management of Turner syndrome is based on an individualised, person-centred approach. It includes:Specialised diagnostic assessment (clinical, hormonal and genetic) Screening for, prevention and treatment of associated complications Clear information provided to the patient and her familyMedical, psychological and social support throughout life, when necessaryDepending on each patient’s needs, medical monitoring and treatment may include:Hormone replacement therapy (oestrogen-progestogen therapy from puberty until the usual age of menopause)Growth hormone treatment during childhood and adolescenceThyroid hormone treatment in the event of hypothyroidismSurgical procedures when necessary (particularly in cardiology or ENT) Fertility preservation procedures when indicated Regular monitoring of bone, metabolic and cardiovascular healthAppropriate treatment of complications that may arise during follow-up, such as obesity, diabetes, high blood pressure or osteoporosis.The aim is to support each patient in understanding her condition and treatment, in order to promote her long-term quality of life. Multidisciplinary team – Erasme Hospital – H.U.BManagement of Turner syndrome is based on close collaboration between several specialists:Paediatric endocrinologists (from HUDERF, as part of the transition to adult care) and adult endocrinologists (Erasme Hospital);Geneticists: Dr Isabelle Vandernoot, Dr Isabelle Migeotte Gynaecologists specialising in fertility: Prof. Anne Delbaere, Dr Mélodie Vander Borght, Dr Ozlem Okutman Cardiologist: Prof. Antoine Bondue ENT specialist: Dr Maxime Niesen Psychologist and neuropsychologist: Marianne Rotsaert, Dr Hichem Slama Psychiatrist: Prof. Oswald Pierre, Social services: Denis StormeSince 2015, a Turner Platform has been organised at Erasme Hospital. It enables patients to meet, during a single day, various specialists from the multidisciplinary team (endocrinologist, gynaecologist from the fertility clinic, cardiologist, ENT specialist and geneticist). This organisation facilitates coordinated, personalised and comprehensive care during a single visit. Patient advice Good adherence to treatment and regular medical follow-up are essential. It is important to comply with recommendations concerning treatments, screening examinations and monitoring for any complications.Adopting a balanced diet and engaging in regular physical activity help reduce the risk of cardiovascular and metabolic complications.A health passport, specifically designed for patients with Turner syndrome, is made available to them. It includes follow-up recommendations adapted to the different stages of life (childhood, adolescence and adulthood) and facilitates coordination of care.If you have any questions or difficulties, the medical team remains your primary point of contact to adapt your care. Transition to adulthood During adolescence, a gradual preparation for the transition to adult care is organised. This stage helps strengthen the young patient’s autonomy, ensure continuity of medical care and transfer all the necessary information to the specialised adult service. The transition is planned in collaboration with the patient, their family, and the paediatric and adult care teams. Focus: Expertise Patients are treated by a certified adult endocrinologist. Hormone assays and genetic tests are performed in a specialised laboratory. An on-call service is available 24 hours a day. Our centre is actively committed to improving knowledge and care for patients with rare endocrine diseases. A local registry has been established. The centre actively contributes to an international database (International Turner Syndrome Registry) dedicated to Turner syndrome. The aim is to gain a better understanding of the disease, optimise follow-up practices, and compare management approaches between different specialised centres. The team receives ongoing training, participates in congresses and seminars, initiates and collaborates on studies, and publishes in the field of gonadal disorders. It also provides training and teaching for students and doctors in training. Our specialists
Turner syndrome
Health issues
Rare and complex epilepsies
Description Epilepsy is a chronic neurological disease. It is common, can first appear at any age and covers a very heterogeneous group of diseases with multiple causes. In one third of cases epileptic seizures continue despite medication (refractory epilepsy).  A considerable number of patients present a rare and distinct epileptic syndrome for which the prognosis for controlling the seizures and neurological development is poor. These rare epilepsies are for the most part of genetic origin. Rare and complex epilepsies affect almost 5 persons in every 10,000 of the population.  Treatment The Epileptology Clinic of the Erasmus Hospital and Queen Fabiola Children’s University Hospital (HUDERF) possesses specific expertise in treating complex epilepsies.  The centre is recognised by the INAMI/RIZIV [Belgian National Institute for Health and Disability Insurance] as an approved Belgian centre for the treatment of refractory epilepsies.  The rooms at our Epilepsy Exploration Unit ere specially equipped for prolonged video EEG monitoring. The Erasmus Hospital is specialised in intracranial EEG monitoring for the pre-surgery assessment of refractory epilepsies while the HUDERF is specialised in treating epilepsy in children. The multidisciplinary approach at the two sites permits a full range of diagnostic and treatment methods, from the latest medicines and ketogenic diet to surgery.   The H.U.B’s Rare Diseases Function provides access to leading edge  genetic diagnostic technologies that make it possible to identify a genetic cause in a large number of patients with rare and complex  epilepsies and thereby permit targeted treatment. Thanks to close cooperation with neuropaediatrics at the Erasmus Hospital and the HUDERF we are able to offer paediatric patients a structured transition to care in adulthood that is adapted specifically to the individual needs of each patient. Our multidisciplinary medical and paramedical care allows us to treat not only epilepsy but also the medical conditions that are often associated with epilepsy. Advice Genetic factors play an important role in epilepsy, especially if the epilepsy first appears in childhood or is associated with developmental disorders.  Specialised genetic testing is then indicated. Several hundred genes are associated with epilepsy. Identifying a genetic cause not only permits a precise diagnosis but also genetic advice, the prognosis and – increasingly frequently – precision treatment. For patients with refractory epilepsy, pre-surgery exploration can lead to a surgical solution (brain surgery, gamma knife, vagus nerve stimulation, deep brain stimulation, Laser Interstitial Thermal Therapy (LITT). Research Other areas of expertise and research activities:Prolonged EEG monitoring at the Intensive Care Unit to diagnose epileptic seizures in seriously ill patientsParticipation in pharmaceutical trials sponsored by the industry on the use of the latest drugsParticipation in research and expertise networks:Epinord (Franco-Belgian intracranial ’EEG expertise group)ERN EpiCARE (European Reference Network for Rare and Complex Epilepsies)The genetic research networks EpiGen, Epi25 and Consortium on Complex Epilepsies of the International League Against Epilepsy (ILAE)Critical Care EEG Monitoring Research Consortium(CCEMRC)  Documents and useful links Epileptology Clinic HUDERF Department of NeuropaediatricsEpilepsy Exploration UnitERN EpiCARE (European Reference Network for Rare and Complex Epilepsies)Epi25 NetworkConsortium on Complex Epilepsies of the International League Against Epilepsy (ILAE)Critical Care EEG Monitoring Research Consortium (CCEMRC)Patients’ associations: https://ligueepilepsie.behttps://www.epilepsieliga.be Our specialists Neurologists specialising in epilepsy: Prof. Chantal Depondt (Head of the Rare Neurological Diseases Clinic)Prof. Nicolas Gaspard (Head of the Department of Neurology)Dr. Benjamin Legros (Head of the Adult Epileptology Clinic and of the Reference Centre for the treatment of Refractory Epilepsy)Paediatricians specialising in epilepsy: Prof. Alec Aeby (Head of the Department of Neuropaediatrics)Dr. Tom Balfroid (Erasmus Hospital)Dr. Cynthia Prigogine (HUDERF)Dr. Claudine Sculier (Erasmus Hospital – Medical consultant at the Epilepsy Exploration Unit)Dr. Pauline Van Gyseghem (HUDERF)
Rare and complex epilepsies